Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature
review informing the EULAR recommendations for the management of difficult-to-treat
rheumatoid arthritis
Objectives To summarise the evidence on diagnostic issues in difficult-to-treat rheumatoid
arthritis (D2T RA) informing the EULAR recommendations for the management of D2T RA.
Methods A systematic literature review (SLR) was performed regarding the optimal confirmation
of a diagnosis of rheumatoid arthritis (RA) and of mimicking diseases and the assessment
of inflammatory disease activity. PubMed and Embase databases were searched up to
December 2019. Relevant papers were selected and appraised. Results Eighty-two papers
were selected for detailed assessment. The identified evidence had several limitations:
(1) no studies were found including D2T RA patients specifically, and only the minority
of studies included RA patients in whom there was explicit doubt about the diagnosis
of RA or presence of inflammatory activity; (2) mostly only correlations were reported,
not directly useful to evaluate the accuracy of detecting inflammatory activity in
clinical practice; (3) heterogeneous, and often suboptimal, reference standards were
used and (4) (thus) only very few studies had a low risk of bias. To ascertain a diagnosis
of RA or relevant mimicking disease, no diagnostic test with sufficient validity and
accuracy was identified. To ascertain inflammatory activity in patients with RA in
general and in those with obesity and fibromyalgia, ultrasonography (US) was studied
most extensively and was found to be the most promising diagnostic test. Conclusions
This SLR highlights the scarcity of high-quality studies regarding diagnostic issues
in D2T RA. No diagnostic tests with sufficient validity and accuracy were found to
confirm nor exclude the diagnosis of RA nor its mimicking diseases in D2T RA patients.
Despite the lack of high-quality direct evidence, US may have an additional value
to assess the presence of inflammatory activity in D2T RA patients, including those
with concomitant obesity or fibromyalgia.